301015: Qingdao Baheal Medical INC. - Summary | Jitta

Qingdao Baheal Medical INC.

CHN:301015

Price
CN¥19.81
Loss Chance
49.2%
4.99JITTA SCORE
169.58%Over Jitta Line
Jitta Ranking
195 / 486
1,904 / 5,271
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (46)
Recent Business Performance (27)
Financial Strength (77)
Return to Shareholders (53)
Competitive Advantage (47)
Jitta Signs
Debt LevelLow Long Term Debt
Revenue and EarningRevenue decline from 2022-2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 40.82% in the last year
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
4.99
169.58%
4.23
> 1,000%
Health Care Distributors
6.90
16.80%
5.28
46.85%
3.01
100.00%
COMPANY DESCRIPTION
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Harle, and Wei Xi Kang brand names. It also provides ophthalmic drugs under the HYCOSAN brand name; tumor and other severe drugs under the Human Albumin and Xospata brand names; anti-aging and cosmeceuticals under the Quanis, Excellula, TRANSINO, and Qingchunbao brand names; diabetes drugs under the Naida, Feburic, and Naite brand names; respiratory and anti-infective products under the Klacid brand name; and medical nutrition under the Nutrasumma brand name. The company was incorporated in 2005 and is based in Qingdao, China. Qingdao Baheal Medical INC. is a subsidiary of BAHEAL Pharmaceutical Holdings Limited.